<DOC>
	<DOCNO>NCT00337389</DOCNO>
	<brief_summary>To compare progression-free survival time ( PFS ) patient treat 5-FU modulated CoFactor ( plus bevacizumab ) 5-FU modulate leucovorin ( plus bevacizumab ) patient Metastatic Colorectal Cancer .</brief_summary>
	<brief_title>Phase III Randomized Study 5-FU , CoFactor , Avastin vs. 5-FU , LV Avastin First-Line Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>1 . Greater equal 18 year age . 2 . Surgically incurable , metastatic disease proven colon rectal adenocarcinoma . 3 . Life expectancy least 3 month . 4 . Histologically confirm metastatic disease . Histological confirmation may waive needle biopsy present significant risk subject clinical setting clinically consistent metastasis colorectal cancer , e.g . surgical finding laparotomy , positive PET scan , synchronous histologically confirm primary tumor typical metastatic pattern ( stage D disease ) . Waiver grant Sponsor , case keep less 10 % total study population . 5 . Measurable disease . At least one unidimensionally measurable lesion diameter ≥10 mm use spiral CT scan ( use spiral CT must document medical record use consistently throughout study ) ≥20 mm use conventional CT MRI scan . 6 . No prior systemic chemotherapy immunotherapy metastatic advance local disease . However patient may radiosensitizing dos fluoropyrimidines ( 5FU capecitabine , without leucovorin levamisole permit ) complete 6 month prior treatment protocol . No prior irinotecan oxaliplatin combination radiotherapy allow . 7 . Prior adjuvant therapy allow complete 6 month prior treatment protocol . Regimens include oxaliplatin irinotecan allow . 8 . ECOG Performance Status 02 Karnofsky performance level 10070 . 9 . Willing able provide write informed consent . 1 . Any prior exposure bevacizumab . 2 . A known intolerance fluoropyrimidine ( 5FU , capecitabine , floxuridine , UFT ) therapy suggestive dihydropyrimidine dehydrogenase ( DPD ) deficiency . 3 . Use follow drug permit protocol : sorivudine ( nucleoside analogue ) , Brivudin™ ( DPD inhibitor ) . 4 . Pregnancy lactation . Women positive ( ) serum urine pregnancy test within 15 day Cycle 1 Week 1 . Women must amenorrheic least 12 consecutive month consider lack potential child bearing . 5 . If sexually active childbearing potential , failure agree use adequate contraception study 60 day discontinuation study medication . 6 . A concurrent infection , include diagnosis FUO evidence possible central line sepsis ( subject must afebrile start therapy ) . 7 . Any unstable oncologic emergency syndrome : superior vena cava syndrome , rise bilirubin needing stent placement , spinal cord compression , active bleeding , etc . 8 . History CNS metastasis , brain tumor , history stroke . 9 . Radiation therapy within 6 week Cycle 1 Week 1 , radiation therapy encompass target lesion select study unless lesion document progression disease . 10 . Major surgery , open biopsy , significant traumatic injury within 4 week Cycle 1 Week 1 , anticipate need major surgical procedure course study . 11 . Fine needle aspiration placement central line catheter within 7 day Cycle 1 Week 1 . 12 . Inadequate bone marrow , liver kidney function define : Serum creatinine 1.5 time upper limit normal , Urine protein creatinine ratio &gt; 1 , Serum bilirubin &gt; 2 time upper limit normal , ANC &lt; 1.5 x 109/L , Hemoglobin &lt; 9.0 g / dL Platelet count &lt; 90 x 109/L , SGOT ( AST ) SGPT ( ALT ) 3 time upper limit normal , 5 time upper limit normal subject document liver metastasis . 13 . Myocardial infarction , transient ischemic attack , cerebral bleeding , translumenal cardiac angiography cardiac stent placement arterial thrombotic event within 12 month prior Cycle 1 Week 1 . 14 . Active , clinically significant cardiovascular symptomatic arterial peripheral vascular disease [ e.g. , uncontrolled hypertension , congestive heart failure , claudication , unstable angina , symptomatic cardiac arrhythmia , New York Heart Association ( NYHA ) Class 2 great ] . 15 . Presence serious nonhealing wound , gastroduodenal ulcer active endoscopy , gastrointestinal perforation intraabdominal abscess , skin ulcer , bone fracture . 16 . INR &gt; 1.5 unless therapeutic dos oral anticoagulant ( e.g . warfarin ) . If , must inrange INR ( usually 23 ) stable dose drug . 17 . Participation another experimental drug study within 4 week prior Cycle 1 Week 1 . 18 . Known suspected anaphylaxis reaction leucovorin allergic reaction drug , opinion Investigator , suggest increase potential hypersensitivity CoFactor study drug include excipients . 19 . Presence organ allograft require immunosuppressive therapy . 20 . Unwilling unable comply study protocol history psychiatric disability judge investigator preclude grant informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Cancer</keyword>
	<keyword>CoFactor</keyword>
	<keyword>Stage IV</keyword>
</DOC>